

Sustainability Report

Message from CStO (Chief Strategy Officer)

We set our 2030 Vision “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society”, and we aim to be a company that continues to take on the challenge of providing innovative solutions as well as solving the social issues such as creating innovative pharmaceuticals and contributing to SDGs (Sustainable Development Goals).

To solve social issues, we promote ESG management based on a long-term perspective that enhances both financial and non-financial value by reflecting ESG elements in business strategies, from the perspectives of E (Environment), S (Society), and G (Governance). We believe that this long-term focused management will lead to sustainable growth of both our company and society.

In our current 5-year business plan, we have identified material issues that must be addressed to achieve sustainable growth as “materiality” and been promoting initiatives that lead to sustainable development of society and business opportunities, such as the creation of innovative pharmaceuticals and improvement of access to healthcare. In addition to the promotion of environmental management and compliance management, we are also working to promote the success and development of a diverse range of people who create our competitive advantages, which is the source of our strengths.

We believe that the pipeline of innovative pharmaceuticals and the value we contribute to our shareholders & investors, employees, and other stakeholders, as well as society and the natural environment, which are created through these efforts, will lead to non-financial value, and we will further promote ESG management in order to enhance mid-to-long-term corporate value.



Director
Senior Executive Officer
Head of Global Corporate Strategy
CStO

Takashi Fukuoka

Sustainability Activities	71
Materiality	73

E Environment	75
• Climate Change	76
• Pollution	79
• Water, Biodiversity	81
• Resource Use and Circular Economy	83

S Social	85
• Our Group Employees	86
• Human Rights	90
• Access to Healthcare	91
• Safety of Pharmaceuticals	95

G Governance	97
• Compliance	98
• Protection of Whistle-blowers, Animal Welfare	101
• Relationship with Business Partners	102
• Prevention of Bribery and Corruption	104

External ESG Evaluations	105
Independent Assurance Report	107
Global Reporting Initiative (GRI) Standards	108
ESG Data	109